Bionano Genomics, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b209a2b6-4cd0-4cf5-9d9c-94eaabaac559/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $28.5M | 2025-01-01 – 2025-12-31 | evidence 0001411690-26-000007 |
| FY 2024 | $30.8M | 2024-01-01 – 2024-12-31 | evidence 0001411690-25-000037 |
| FY 2023 | $36.1M | 2023-01-01 – 2023-12-31 | evidence 0001411690-24-000013 |
| FY 2022 | $27.8M | 2022-01-01 – 2022-12-31 | evidence 0001411690-23-000010 |
| FY 2021 | $18.0M | 2021-01-01 – 2021-12-31 | evidence 0001411690-22-000007 |
| FY 2020 | $8.5M | 2020-01-01 – 2020-12-31 | evidence 0001411690-22-000007 |
| FY 2019 | $10.1M | 2019-01-01 – 2019-12-31 | evidence 0001411690-20-000006 |
| FY 2018 | $12.0M | 2018-01-01 – 2018-12-31 | evidence 0001411690-20-000006 |
| FY 2017 | $9.5M | 2017-01-01 – 2017-12-31 | evidence 0001628280-19-002959 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Bionano Genomics, Inc. — all facts · Net Income · Operating Income